Matches in SemOpenAlex for { <https://semopenalex.org/work/W3108204080> ?p ?o ?g. }
- W3108204080 endingPage "577" @default.
- W3108204080 startingPage "557" @default.
- W3108204080 abstract "Biological medicines have increased the cost of cancer treatments, which also raises concerns about sustainability. In Brazil, three monoclonal antibodies (mAbs)-bevacizumab, cetuximab, and panitumumab-are indicated for the treatment of metastatic colorectal cancer (mCRC) but not currently funded by the Unified Health System (SUS). However, successful litigation has led to funding in some cases.Our objective was to evaluate the budgetary impact of including the mAbs bevacizumab, cetuximab, and panitumumab in standard chemotherapy for the treatment of mCRC within the SUS of Minas Gerais (MG), Brazil.A budget impact analysis of incorporating mAbs as first-line treatment of mCRC in MG was explored. The perspective taken was that of the Brazilian SUS, and a 5-year time horizon was applied. Data were collected from lawsuits undertaken between January 2009 and December 2016, and the model was populated with data from national databases and published sources. Costs are expressed in $US.In total, 351 lawsuits resulted in funding for first-line treatment with mAbs for mCRC. The three alternative scenarios analyzed resulted in cost increases of 348-395% compared with the reference scenario. The use of panitumumab had a budgetary impact of $US103,360,980 compared with the reference scenario over a 5-year time horizon, and bevacizumab and cetuximab had budgetary impacts of $US111,334,890 and 113,772,870, respectively. The use of the anti-epidermal growth factor receptor (EGFR) mAbs (cetuximab and panitumumab) is restricted to the approximately 41% of patients with KRAS mutations, so the best cost alternative for incorporation would be the combination of panitumumab and bevacizumab, with a cost of approximately $US106 million.These results highlight the appreciable costs for incorporating bevacizumab, cetuximab, and panitumumab into the SUS. Appreciable discounts are likely to be necessary before incorporation of these mAbs is approved." @default.
- W3108204080 created "2020-12-07" @default.
- W3108204080 creator A5001513306 @default.
- W3108204080 creator A5004578430 @default.
- W3108204080 creator A5004916112 @default.
- W3108204080 creator A5014750137 @default.
- W3108204080 creator A5017350129 @default.
- W3108204080 creator A5028480298 @default.
- W3108204080 creator A5037367909 @default.
- W3108204080 creator A5048467725 @default.
- W3108204080 creator A5070568819 @default.
- W3108204080 creator A5088210795 @default.
- W3108204080 creator A5091690104 @default.
- W3108204080 date "2021-01-28" @default.
- W3108204080 modified "2023-10-06" @default.
- W3108204080 title "The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil" @default.
- W3108204080 cites W1606278307 @default.
- W3108204080 cites W1845370611 @default.
- W3108204080 cites W1990021167 @default.
- W3108204080 cites W1995202401 @default.
- W3108204080 cites W2001109816 @default.
- W3108204080 cites W2002226820 @default.
- W3108204080 cites W2002952144 @default.
- W3108204080 cites W2005348280 @default.
- W3108204080 cites W2029862269 @default.
- W3108204080 cites W2073330002 @default.
- W3108204080 cites W2078118224 @default.
- W3108204080 cites W2085633477 @default.
- W3108204080 cites W2095201384 @default.
- W3108204080 cites W2098354753 @default.
- W3108204080 cites W2103789431 @default.
- W3108204080 cites W2104115221 @default.
- W3108204080 cites W2110229025 @default.
- W3108204080 cites W2119452230 @default.
- W3108204080 cites W2119679249 @default.
- W3108204080 cites W2121454917 @default.
- W3108204080 cites W2124036501 @default.
- W3108204080 cites W2134142320 @default.
- W3108204080 cites W2143401180 @default.
- W3108204080 cites W2157769714 @default.
- W3108204080 cites W2161097769 @default.
- W3108204080 cites W2166191933 @default.
- W3108204080 cites W2300108605 @default.
- W3108204080 cites W2325774456 @default.
- W3108204080 cites W2468746344 @default.
- W3108204080 cites W2528002479 @default.
- W3108204080 cites W2529341209 @default.
- W3108204080 cites W2530765404 @default.
- W3108204080 cites W2531319683 @default.
- W3108204080 cites W2587436993 @default.
- W3108204080 cites W2606435196 @default.
- W3108204080 cites W2606920054 @default.
- W3108204080 cites W2607062403 @default.
- W3108204080 cites W2623385419 @default.
- W3108204080 cites W2690524270 @default.
- W3108204080 cites W2712978371 @default.
- W3108204080 cites W2742587582 @default.
- W3108204080 cites W2743070149 @default.
- W3108204080 cites W2761198089 @default.
- W3108204080 cites W2766981306 @default.
- W3108204080 cites W2767626025 @default.
- W3108204080 cites W2779228944 @default.
- W3108204080 cites W2787322606 @default.
- W3108204080 cites W2793004212 @default.
- W3108204080 cites W2801822890 @default.
- W3108204080 cites W2803358834 @default.
- W3108204080 cites W2804005679 @default.
- W3108204080 cites W2808193378 @default.
- W3108204080 cites W2884436616 @default.
- W3108204080 cites W2889646458 @default.
- W3108204080 cites W2899026268 @default.
- W3108204080 cites W2902129153 @default.
- W3108204080 cites W2915961297 @default.
- W3108204080 cites W2917884620 @default.
- W3108204080 cites W2924176005 @default.
- W3108204080 cites W2942572942 @default.
- W3108204080 cites W2947717819 @default.
- W3108204080 cites W2953978036 @default.
- W3108204080 cites W2977497532 @default.
- W3108204080 cites W2979456429 @default.
- W3108204080 cites W2980889792 @default.
- W3108204080 cites W2981122695 @default.
- W3108204080 cites W2981391876 @default.
- W3108204080 cites W2984738731 @default.
- W3108204080 cites W3009766810 @default.
- W3108204080 cites W3041104619 @default.
- W3108204080 cites W2145574613 @default.
- W3108204080 doi "https://doi.org/10.1007/s40258-020-00626-0" @default.
- W3108204080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33506317" @default.
- W3108204080 hasPublicationYear "2021" @default.
- W3108204080 type Work @default.
- W3108204080 sameAs 3108204080 @default.
- W3108204080 citedByCount "2" @default.
- W3108204080 countsByYear W31082040802021 @default.
- W3108204080 crossrefType "journal-article" @default.
- W3108204080 hasAuthorship W3108204080A5001513306 @default.
- W3108204080 hasAuthorship W3108204080A5004578430 @default.
- W3108204080 hasAuthorship W3108204080A5004916112 @default.